1. Saudi Arabia Stocks

  2. •

    Healthcare

  3. •

    Medical - Specialties
Arabian International Healthcare Holding Company

Arabian International Healthcare Holding Company

9530.SR
Arabian International Healthcare Holding CompanySA flagSaudi Exchange
20.66
SAR
- -
- -
408.86MMarket Cap
Arabian International Healthcare Holding Company
9530.SR
(Saudi Exchange)

Recent

price

20.66

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
FRC
34.85
40.93
30.93
32.17
40.77
37.36
- -
Revenue per Share
2.06
4.79
4.12
1.02
1.92
-3.37
- -
Basic EPS, GAAP
-1.22
11.07
6.32
2.69
0.2
5.11
- -
Free Cash Flow per Basic Share
0.84
1.54
4.13
3
1
- -
- -
Dividend per Share
4.34
16.13
15.77
13.9
14.82
11.55
- -
Book Value per Share
13.29
16.61
16.55
9.76
12.09
13.38
- -
Tangible Book Value per Share
20
20
20
20
20
20
- -
Basic Weighted Avg Shares
697
819
619
643
807
739
842
Sales/Revenue/Turnover
11.6
12.09
11.33
6.31
6.6
7.3
7.78
Operating Margin (%)
8
8
7
10
15
18
18
Depreciation Expense
41
96
82
20
38
-67
24
Net Income, GAAP
27.5
20.03
12.19
29.75
21.46
- -
26.24
Effective Tax Rate (%)
5.9
11.7
13.31
3.19
4.72
-9.01
2.8
Profit Margin (%)
266
434
403
236
399
354
383
Working Capital
12
110
82
83
218
180
108
LT Debt
266
332
333
338
359
293
365
Total Equity
- -
11.19
9.89
4.09
5.11
- -
7.04
Return on Invested Capital (%)
- -
17.71
14.86
4.04
7.53
- -
7.81
Return on Capital (%)
- -
46.8
25.81
6.91
13.34
-25.53
9.88
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
2.84%
24.75%
Free Cash Flow
- -
441.75%
-102.05%
Net Income, GAAP
- -
-82.7%
-135.42%
Sales/Revenue/Turnover
- -
2.11%
13.92%
Total Cash Common Dividend
- -
- -
-38.1%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
807
2024
- -
- -
- -
- -
739
2025
- -
- -
- -
- -
842

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1.92
2024
- -
- -
- -
- -
-3.37
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Hyperfine, Inc. (HYPR)
STERIS plc (STE)
Orthometrix, Inc. (OMRX)
Chison Medical Technologies Co., Ltd. (688358.SS)
Subgen AI AB (SUBGEN.ST)
Avon Technologies Plc (AVNBF)
Business
Arabian International Healthcare Holding Company (Tibbiyah) provides integrated medical solutions to healthcare providers in Saudi Arabia through its subsidiaries, operating primarily in medical devices, medical supplies, and clinical and pharmaceutical segments. The company distributes and maintains a wide range of products including cardiology equipment, intensive care systems, oncology solutions, rehabilitation devices, infection prevention technologies, hospital infrastructure, gene sequencing laboratories, anesthesia machines, hospital beds and medical furniture, lab furniture solutions, biobanking systems, hospital information technology, surgical room solutions, laboratories, filter ventilation systems, prosthetics, dental and veterinary equipment, and cosmetic products; it also offers medical services at clinics and sells health and beauty related medicines. Tibbiyah operates exclusively in the Kingdom of Saudi Arabia from its headquarters in Riyadh's Business Gate Complex and was founded in 2013 by Al Faisaliah Group to consolidate its healthcare subsidiaries such as Al Faisaliah Medical Systems Company, International Medical Supplies Company, International Healthcare Optimization Company, and Health Care Technologies Company. Recent developments include a November 2025 conditional share purchase agreement to acquire a 49% stake in NephroCare Health Services Saudi Arabia for SAR 279,829, forming a partnership with NephroPlus to expand in renal care and dialysis services; completion of the SAR 35 million acquisition of Al Hammad Medical Services in 2024; regulatory approval for a 51% acquisition of a UAE-based entity; and a May 2025 SAR 67 million contract with the Ministry of Health for cardiac systems.